Personalized cell therapy aims to free transplant patients from lifelong drugs
NCT ID NCT05234190
Summary
This study is testing a new, personalized cell therapy called QEL-001. It is made from a patient's own immune cells, which are modified in a lab to help the body accept a donated liver. The goal is to see if this therapy is safe and if it can allow patients to safely stop taking standard anti-rejection medications long-term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
G. Gergorio Maranon
Madrid, Spain
-
H. Clinic Barcelona
Barcelona, Spain
-
H. Saint Luc
Brussels, Belgium
-
Hopital Erasme
Brussels, Belgium
-
Hospital Reina Sofia
Córdoba, Spain
-
King's College Hospital NHS Foundation Trust
London, SE5 9RS, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, United Kingdom
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
UZ Leuven
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.